Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm

2006298 citationsJournal Article

Authors

David G. Pfister · Memorial Sloan Kettering Cancer Center

Yungpo Bernard Su · Memorial Sloan Kettering Cancer Center

Dennis H. Kraus · Memorial Sloan Kettering Cancer Center

Suzanne L. Wolden · Memorial Sloan Kettering Cancer Center

Eric Lis · Memorial Sloan Kettering Cancer Center

Timothy Aliff · Memorial Sloan Kettering Cancer Center

Andrew J. Zahalsky

Abstract

This regimen is not currently recommended outside of the clinical trial setting. Further investigation of its safety profile is needed. However, preliminary efficacy is encouraging, and further development of this targeted combined-modality paradigm is warranted.

Topics & Keywords

Head and Neck Cancer Studies Salivary Gland Tumors Diagnosis and Treatment Head and Neck Surgical Oncology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 24, Issue 7, pp. 1072-1078

DOI: 10.1200/jco.2004.00.1792

Field-Weighted Citation Impact: 34.00